# PR.21 (NCT04663997)

> 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

No report yet. It can be ordered.

- Drugs tested: 177Lu-PSMA-617
- Indication: PSMA-positive metastatic castration-resistant prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04663997
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Canadian Cancer Trials Group
- Conditions: Prostate Cancer
- Interventions: 177Lu-PSMA-617; Docetaxel
- Enrollment: 200
- Primary outcome: Progression-free survival

## Questions raised in the commentary

_Automated from the 40 newest of 45 indexed sources (Jun 2024 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether docetaxel or lutetium PSMA should come first
- How to interpret overall survival alongside radiographic progression-free survival
- How crossover affects interpretation of overall survival
- Which patient features should guide treatment selection

Also discussed: patient-reported quality of life.

## Indexed commentary on PR.21 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 25 posts on X
- 11 podcast episodes
- 9 YouTube videos

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=pr-21-nct04663997

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04663997", "email": "<work email>"}; the inbox owner confirms by the emailed link.